Gap DUST 12: We need to determine if technologies are available or need to be developed to evaluate celestial dust toxicity and/or volatile composition in situ.
Last Published:  07/30/21 01:05:31 PM (Central)
Responsible Element: Exploration Medical Capability (ExMC)
Status: Closed
Closure Rationale
A PEL for lunar dust exposure has been defined and codified in the NASA Standard (reference PEL and NASA standard link from prior slide). Engineering controls will need to be instituted to maintain human exposure to celestial dust at acceptable levels. At this time, there is no further ExMC research planned in this area. If the engineering controls are unsuccessful, then work in this area may need to resume in the future.
Closure Documentation:
No Closure Documentation Available
Description
The current toxicology evaluations for spaceflight use traditional technologies to identify toxicants associated with the spaceflight environment. In the toxicology field there are emerging “organ on a chip” methodologies that may have merit as a tool in addressing materials toxicity (e.g., at the location of an asteroid or on the surface of Mars) rather than in returning samples. These new technologies will be critical for the evaluation of spaceflight environments exploration class missions provided increased technology with decreased time and mass. If sample return is possible, these technologies may also be employed as a relative toxicity screening tool to help guide the research needed to establish a PEL and possibly reduce the scope of animal testing.

Research Approach

The toxicology discipline scientist will monitor current commercial technologies and work with other NASA groups to understand capabilities. Recommendations for future technologies are expected by 2018. In the interim, small scale pilot projects are recommended to compare results from toxicity endpoints evaluated in the extensive lunar dust research to existing organ chip platforms in order to determine whether or not these technologies would be viable for future adaptation and use in situ. Same potential collaborators as Dust 11, in addition to outside experts and stakeholders.
Target for Closure
Identification and evaluation of technologies to monitor celestial dust toxicity or volatile composition.
Mappings
Risk Risk of Adverse Health and Performance Effects of Celestial Dust Exposure
You are here! Gap DUST 12: We need to determine if technologies are available or need to be developed to evaluate celestial dust toxicity and/or volatile composition in situ.

Multi-Disciplinary Research Plans

Documentation:
No Documentation Available